XML 60 R48.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENT REPORTING - Summary of Significant Research and Development and General and Administrative Expense to CODM (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Revenue $ 18   $ 49,898   $ 47 $ 67,482
Platform development and early-stage research expenses [Abstract]            
Depreciation and amortization         773 2,235
Total research and development expenses 12,768   17,225   26,356 30,568
General and administrative expense            
Total general and administrative expenses 9,127   8,527   17,680 16,955
Total operating expenses 21,895   25,752   44,036 47,523
Operating (loss) income (21,877)   24,146   (43,989) 19,959
Total other (expense) income (1,643)   8,603   (96) 21,378
(Loss) income from operations (23,520)   32,749   (44,085) 41,337
Net (loss) income (23,520) $ (20,565) 32,749 $ 8,588 (44,085) 41,337
Operating Segment            
Segment Reporting Information [Line Items]            
Revenue 18   49,898   47 67,482
Platform development and early-stage research expenses [Abstract]            
Employee-related costs (including share-based compensation) 4,766   5,368   10,066 10,748
Laboratory supplies and services 557   670   1,011 1,414
CMOs and outsourced research and development 277   112   333 340
Facility-related costs, laboratory equipment, and maintenance 807   818   1,535 1,628
Depreciation and amortization 330   842   670 1,733
Licensing fees and other research and development costs 515   641   1,021 1,488
Total research and development expenses 12,768   17,225   26,356 30,568
General and administrative expense            
Employee-related costs (including share-based compensation) 5,730   5,099   11,190 10,108
Consulting and professional services 1,665   1,487   3,201 2,954
Other operating expenses and all other costs 1,732   1,941   3,289 3,893
Total general and administrative expenses 9,127   8,527   17,680 16,955
Total operating expenses 21,895   25,752   44,036 47,523
Operating (loss) income (21,877)   24,146   (43,989) 19,959
Total other (expense) income (1,643)   8,603   (96) 21,378
(Loss) income from operations (23,520)   32,749   (44,085) 41,337
Net (loss) income (23,520)   32,749   (44,085) 41,337
PBGENE-HBV external development costs | Operating Segment            
Direct research and development expenses by product candidate:            
External development costs (credits) 1,378   7,654   2,979 10,710
PBGENE-DMD external development costs | Operating Segment            
Direct research and development expenses by product candidate:            
External development costs (credits) 4,163   156   6,601 331
PBGENE-3243 external development (credits) costs | Operating Segment            
Direct research and development expenses by product candidate:            
External development costs (credits) $ (25)   $ 964   $ 2,140 $ 2,176